Protein C, human (Ceprotin)

Human protein C

History of changes in EMA indication

• 2001-07-16: Initial authorization as Ceprotin
• Uncertain date: CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans, coumarin-induced skin necrosis, and venous thrombotic events in patients with severe congenital protein C deficiency.

Also known as

• Brand name: Ceprotin